AP
KPTI icon

Aspect Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Aspect Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-391
Closed -$2.88K – 727
2025
Q4 		$2.88K Buy
+391
New +$2.39K ﹤0.01% 465

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Aspect Partners's KPTI Position: Q1 2026 in Review

Aspect Partners sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 391 shares — an estimated $2.88K sold.

Aspect Partners first reported a position in KPTI in Q4 2025 and held it in 1 quarter. The position peaked at $2.88K in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Aspect Partners reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aspect Partners sold 391 Karyopharm Therapeutics shares in Q1 2026, an estimated $2.88K.
  • Aspect Partners first reported a position in Karyopharm Therapeutics in Q4 2025 and held it in 1 quarter.
  • Aspect Partners's Karyopharm Therapeutics position peaked at $2.88K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Aspect Partners's 13F filing for Q1 2026, filed 2 Apr 2026.